Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | TEK | Q02763 | 9/20 | 0.53 |
| ▸ | FLT1 | P17948 | 1/20 | 0.53 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 1/20 | 0.50 |
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16008305 | 1.00 | KDR (1.00) | KDRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL16008043 | 0.92 | KDR (1.00) | KDRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL16008046 | 0.92 | KDR (1.00) | KDRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL16008185 | 0.88 | KDR (1.00) | KDRMEN1KMT2ARAB9AMAPT | |
| SCHEMBL16008183 | 0.88 | KDR (1.00) | KDRMEN1KMT2ARAB9AMAPT | |
| SCHEMBL16008186 | 0.88 | KDR (1.00) | KDRMEN1KMT2ARAB9AMAPT | |
| SCHEMBL16008163 | 0.80 | KDR (0.85) | KDRMEN1KMT2ARAB9AMAPT | |
| SCHEMBL16008166 | 0.80 | KDR (0.85) | KDRMEN1KMT2ARAB9AMAPT | |
| SCHEMBL16008165 | 0.80 | KDR (0.85) | KDRMEN1KMT2ARAB9AMAPT | |
| SCHEMBL31504006 | 0.79 | KDR (0.66) | KDRNPC1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321721-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | claimed |
| WO-2014138452-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | claimed |
| US-20140256819-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | claimed |
| US-9321721-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| WO-2014138452-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-20140256819-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256819-A1 | KINASE INHIBITORS | CDK1, MAP3K1, MAPK1 | KDR 322/4885MEN1 1158/4885KMT2A 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.